Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer

In a placebo-controlled randomised study of the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate and docetaxel in metastatic prostate cancer with bone metastases (n=116), no significant differences in progression-free and overall survival were observed. To evaluate pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, P, Thall, P F, Wen, S, Bucana, C, Jones, D, Horne, E, Oh, W K, Morris, M J, Lee, Y-C, Logothetis, C J, Lin, S-H, Fidler, I J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579696/
https://www.ncbi.nlm.nih.gov/pubmed/18841158
http://dx.doi.org/10.1038/sj.bjc.6604706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579696/
https://www.ncbi.nlm.nih.gov/pubmed/18841158
http://dx.doi.org/10.1038/sj.bjc.6604706

Ejemplares similares